Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Immunodetection of human topoisomerase I-DNA covalent complexesHistone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicMulti-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.Evaluation of the BH3-only protein Puma as a direct Bak activatorRecent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions.Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cellsReprogramming cancer cells: overview & current progress.Investigating cell therapy for inflammatory bowel disease.Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy.Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm.Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance.Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes.Getting a GRP on histone deacetylase inhibitor selectivity.Measurement of BH3-only protein tolerance.
P2860
Q24597424-871B7250-58AF-4BAB-8BE4-DD2EDA34F4FDQ27324108-36217051-EFDC-401B-AEF3-02A6AA83310DQ33808800-E28FFC85-8D45-47D6-9283-4A8A746A6C21Q34817365-43FD8EFE-926E-4272-B37F-A1515596EE6FQ35525569-22646475-0076-4BBC-A4B9-12A513D428FCQ37428715-36EDFFBE-E4AC-4A20-9C14-007BF2270E01Q38058956-5C653A3A-6F51-4DDA-AE54-DFFC5D0C834AQ38445385-3C9F9ECA-2B67-40CB-859F-E2465D52A6B2Q38806067-576B82B1-F6F4-43F4-81E2-780389567DDAQ38817393-F0000C42-7D46-4C2A-8F2B-FE44535AF407Q38897538-5B9BFE9C-801D-4420-8CF0-67501176FF90Q39303314-87CD1B88-CE7A-4893-A8D8-45753D4933D0Q39437389-BB66B0BA-BECA-4D17-8404-2B775D4AE0AAQ39544646-790D6D44-4825-4094-A7CF-2ED96646BBCEQ41906775-9D59F304-2C80-4523-827C-AB199729E58DQ42072372-75F008F9-F91D-4C44-A126-F4A1ED332078Q45808456-D072DDFA-C1EE-4F48-A280-6C6C991DE1FDQ47624759-2A4DD247-CF7F-4A8E-8181-1A6BAD604B6C
P2860
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cytotoxicity of farnesyltransf ...... ibition and Bim up-regulation.
@ast
Cytotoxicity of farnesyltransf ...... ibition and Bim up-regulation.
@en
type
label
Cytotoxicity of farnesyltransf ...... ibition and Bim up-regulation.
@ast
Cytotoxicity of farnesyltransf ...... ibition and Bim up-regulation.
@en
prefLabel
Cytotoxicity of farnesyltransf ...... ibition and Bim up-regulation.
@ast
Cytotoxicity of farnesyltransf ...... ibition and Bim up-regulation.
@en
P2093
P2860
P1433
P1476
Cytotoxicity of farnesyltransf ...... hibition and Bim up-regulation
@en
P2093
Husheng Ding
Jennifer Hackbarth
Kevin L Peterson
Paula A Schneider
Thomas E Witzig
X Wei Meng
P2860
P304
P356
10.1182/BLOOD-2011-02-334870
P407
P577
2011-06-14T00:00:00Z